Full Text:
<8>
CLC number:
On-line Access: 2026-03-26
Received: 2025-07-31
Revision Accepted: 2025-11-30
Crosschecked: 0000-00-00
Cited:
Clicked: 14
|
Self-assembled polyoxometalate–phenolic nanodrugs integrated with dissolving microneedles for hypertrophic scar combination therapy
| |||||||||||||
Manyi Du. Self-assembled polyoxometalate–phenolic nanodrugs integrated with dissolving microneedles for hypertrophic scar combination therapy[J]. Journal of Zhejiang University Science D, 2026, 9(2): 318 - 334.
@article{title="Self-assembled polyoxometalate–phenolic nanodrugs integrated with dissolving microneedles for hypertrophic scar combination therapy",
author="Manyi Du",
journal="Journal of Zhejiang University Science D",
volume="9",
number="2",
pages="318 - 334",
year="2026",
publisher="Zhejiang University Press & Springer",
doi="10.1631/bdm.2500389"
}
%0 Journal Article
%T Self-assembled polyoxometalate–phenolic nanodrugs integrated with dissolving microneedles for hypertrophic scar combination therapy
%A Manyi Du
%J Journal of Zhejiang University SCIENCE D
%V 9
%N 2
%P 318 - 334
%@ 1869-1951
%D 2026
%I Zhejiang University Press & Springer
%DOI 10.1631/bdm.2500389
TY - JOUR
T1 - Self-assembled polyoxometalate–phenolic nanodrugs integrated with dissolving microneedles for hypertrophic scar combination therapy
A1 - Manyi Du
J0 - Journal of Zhejiang University Science D
VL - 9
IS - 2
SP - 318
EP - 334
%@ 1869-1951
Y1 - 2026
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/bdm.2500389
Abstract: The clinical management of hypertrophic scars (HSs) remains challenging due to their complex etiology and heterogeneous morphology, underscoring the need for multitarget treatment strategies. In this study, we developed a nanocomposite system constructed through the metal–phenolic network–mediated self-assembly of molybdenum polyoxometalate ({Mo154}) and epigallocatechin gallate (EGCG), followed by chitosan encapsulation, to generate chitosan-encapsulated {Mo154}/EGCG (CME) nanoparticles. These nanoparticles were integrated into dissolvable microneedles (CME@MN) to enable transdermal administration. Under near-infrared laser irradiation, CME exhibited a three-pronged therapeutic effect: suppression of collagen overproduction and excessive extracellular matrix (ECM) deposition in human keloid fibroblasts, regulation of proliferation and migration in human umbilical vein endothelial cells, and reprogramming of macrophages toward a proinflammatory M1 phenotype. In vivo, CME@MN patches preferentially accumulated within scar tissue, where they normalized ECM organization, improved collagen fiber rearrangement, and attenuated fibroblast activity through photothermal-enhanced mechanisms while maintaining an excellent safety profile. The CME@MN system represents a potentially transformative approach to HS management by offering a unified platform that simultaneously targets the fibrotic, angiogenic, and inflammatory components of scar pathogenesis.
Open peer comments: Debate/Discuss/Question/Opinion
<1>